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An 83-year-old male was evaluated by the Renal Service because of
an increase in serum creatinine from 1.7 mg/dl to 3.5 mg/dl over a
48-hour period after cardiac catheterization.
He had hypertension for more than 30 years and non-insulin-depen-
dent diabetes mellitus for approximately 25 years. One year ago, he
sustained an inferior wall myocardial infarction and subsequently
underwent two percutaneous transluminal coronary angioplasty proce-
dures. Since that time he had been free of chest pain and had had
minimal evidence of congestive cardiac failure.
The current admission was prompted by progressive shortness of
breath over several days; on presentation to the emergency room he
was found to have atrial fibrillation and severe pulmonary edema. He
was intubated and admitted to the coronary care unit. A non-Q-wave
myocardial infarction was diagnosed and, after a prolonged course
marked by recurrent episodes of supraventricular tachyarrythmias, he
became hemodynamically stable. Blood urea nitrogen and creatinine
were 24 mg/dl and 1.9 mg/dl, respectively, at the time of admission and
23 mg/dl and 1.7 mg/dl, respectively, when he was discharged from the
coronary care unit. Cardiac catheterization was performed to evaluate
his coronary circulation; normal saline was administered intravenously
prior to the procedure (50 mllhr) and mannitol, 25 g, was administered
intravenously immediately after the procedure. Intravenous normal
saline was continued at a rate of 100 mI/hr for 8 hours post catheter-
ization but, despite positive fluid balance, the serum creatinine in-
creased to 2.3 mg/dl. Over the subsequent 24 hours, his urine output
decreased to 900 ml124 hr and the serum creatinine increased further to
3.5 mg/dl. His blood pressure remained normal, and he had no signs of
hemodynamic instability over the 48-hr post-catheterization period.
Medications included digoxin, a beta-blocker, subcutaneous heparin,
and enteric-coated aspirin; no known nephrotoxic agents had been
administered, other than the contrast agent (50 ml Omnipaque, a low
osmolar agent) used during the cardiac catheterization procedure.
On physical examination, the patient was alert, cooperative, and in
no obvious distress. His blood pressure was 140/80mm Hg in the supine
position; the pulse rate was 90 beats/mm and regular; and he was
afebrile. Cardiac examination disclosed an S4 gallop with no murmurs,
and his lungs were clear to auscultation. Abdominal examination was
unremarkable and peripheral edema was absent.
Laboratory studies revealed: serum sodium, 133 mEq/liter; potas-
sium, 4.2 mEq/liter; chloride, 101 mEq/Iiter; total carbon dioxide, 26
mM/liter; blood urea nitrogen, 37 mg/dl; serum creatinine, 3.5 mg/dl;
calcium, 8.0 mg/dl; phosphorus, 4.4 mg/dl; and albumin, 2.6 g/dl. The
hemoglobin was 10.9 g/dl; hematocrit, 32.7%; white blood cell count,
8300 mm3; and platelet count, 315,000 mm3. Urinalysis revealed: pH,
5.0; protein, 30 mg/dl; occasional red blood cells/high-power field, and
occasional granular casts.
Over the subsequent 72 hours, his fluid intake was adjusted to match
his urine output. The serum creatinine increased to 4.2 mg/dl, and his
urine output gradually increased to 1400 ml/24 hr without additional
therapy. The following day he experienced another acute myocardial
infarction, became markedly hypotensive, and required intubation.
Intravenous furosemide, 40 mg/hr over 10 hrs, was given on each of 5
successive days; the urine output increased to 2000 ml/24 hr. The serum
creatinine peaked at 5.6 mg/dl but fell during the following week to the
admission value of 1.7 mg/dl. He subsequently underwent successful
triple-vessel coronary bypass surgery without additional renal insult.
He was discharged home 12 days postoperatively with stable renal
function.
Discussion
DR. EDWARD P. NORD (Associate Professor of Medicine;
Chief, Division of Nephrology; Department of Medicine;
School of Medicine; State University of New York at Stony
Brook, Stony Brook, New York): This Forum is devoted to a
discussion of endothelin (ET) in part because evidence has been
adduced recently to incriminate ET in the pathophysiology of
contrast-induced nephropathy (as well as a number of other
disorders, such as ischemic acute tubular necrosis and cyclo-
sporine nephrotoxicity). Before reviewing that evidence, how-
ever, I will discuss our current state of knowledge about ET in
general, with special emphasis on its sites and mechanisms of
action in the kidney, its sites of renal production, and its
possible physiologic significance in various aspects of renal
function.
Presentation of this Forum is made possible by grants from Merck
Sharp & Dohme International; Amgen, Incorporated; Dialysis Clinic,
Incorporated; Parke-Davis, Incorporated; and Marion Merrell Dow,
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© 1993 by the International Society of Nephrology
General considerations
Endothelin, a recently identified, novel peptide, is a very
potent vasoconstrictor [1]. Three isoforms of human ET have
been identified to date: ET-l, ET-2, and ET-3 [2]. The 21-
residue peptides differ from one another, with the greatest
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Fig. 1. Amino acid sequence of endothelin-1,
endothelin-2, and endothelin-3, Residues
differing from those in endothelin-l are
highlighted, N, amino terminal; C, carboxyl
terminal.
variation in amino acids occurring at residues 4—7(Fig. 1). The
sequence of this variable region might well determine the
different functional characteristics of the different isopeptides.
Early studies identified the endothelial cell as the prime
synthesis site of the peptide, and vascular smooth muscle cells
as the target tissue [3]; evidence is accumulating, however, that
certain non-endothelial cells synthesize the peptide and that
certain non-myogenic cells respond to ET stimulation. For
example, ET-like immunoreactivity has been demonstrated by
immunohistochemistry in the paraventricular and supraoptic
nuclear neurons and their terminals in the posterior pituitary of
the pig and the rat [4]. In-situ hybridization localized ET mRNA
to paraventricular nuclear neurons. Endothelin-like immunore-
activity products in the posterior pituitary of the rat were
depleted by water deprivation; this finding raised the intriguing
possibility that ET and arginine vasopressin (AVP) are released
by a common stimulus, and that ET, in some manner, might be
involved in water homeostasis [4]. Separate studies have shown
that cultured rat and bovine parathyroid cells (but not endothe-
hal cells) and cultured human breast epithelial cells (but not
stromal cells) produce the peptide [5, 6]. In addition, a variety
of non-myogenic cells have now been shown to respond to ET,
including cultured osteoblasts [7] and Swiss 3T3 fibroblasts [8].
These data thus demonstrate that ET production and sites of
action are not confined to the vasculature. The precise physio-
logic role of ET and the factors that elicit its production in
extravascular sites remain to be elucidated.
Sites of action
Accumulating evidence suggests that ET plays a role in a
variety of physiologic events in the kidney. While initial work
focused on the glomerular tuft, the observation that the vast
majority of ET receptors in the kidney are located in the
medulla [9] prompted us and others to explore the nature of the
cell type involved, the mechanism of action of ET, and its
physiologic role in non-glomerular structures.
Two types of ET receptors have been cloned so far; they
differ from one another at the functional level by the nature of
the peptides recognized. The cDNA encoding a bovine lung ET
receptor transfected into COS cells (SV4O transformed African
Green monkey kidney) showed a high affinity for ET-l (kD 0.18
nM) but low affinity for ET-3 (kD 900 nM) [10]. Northern blot
analysis of mRNA isolated from different organs showed that
receptor mRNA was expressed in highest amounts in central
nervous system, heart, and lung, with lesser amounts identified
in other tissues, including kidney. In a second study using poly
(A+) RNA from rat lung, the cDNA encoding the ET receptor
was transfected into COS-7 and COS-S cells; displacement of
'25I-labeled ET- 1 occurred with all three ET isopeptides, ET-l,
ET-2, and ET-3 [11]. Northern blot analysis of rat organ mRNA
N Endothelin-1
N Endothelin-2
N Endothelin-3
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showed high expression of the receptor in brain, lung, and
heart; lower expression in other organs, including kidney; but
no expression in aortic smooth muscle cells. The ET receptor
cloned more recently from cultured rat smooth muscle cells
(AlO) had a high affinity for ET-l and ET-2 but a low affinity for
ET-3; this receptor also was expressed primarily in lung and
heart, with lower levels of expression found in kidney [12].
In summary, according to current nomenclature for ET
receptors, the ETA receptor recognizes ET-l and ET-2, and the
ETB receptor recognizes ET-l, ET-2, and ET-3. Although data
from the animal studies I cited cannot identify the precise
cellular location of the cloned receptor within a particular
organ, studies of cultured vascular smooth muscle cells indicate
that the major ET receptor in the vasculature is ETA [12].
With this background, I will now consider the nature of the
ET receptor present on different cellular structures within the
kidney. Conflicting evidence exists regarding glomerular ET
receptors. Using membrane fragments prepared from isolated
rat glomeruli, Martin and coworkers reported the presence of a
single class of high-affinity receptors (kD 1.31 nM, Bmax 5831
fmollmg protein) that, in retrospect, correspond to the ETB
variety [13]. Gauquelin and associates used a similar prepara-
tion and likewise reported a single class of receptors (kD 0.20
nM, Bmax 450 fmol/mg protein) [14]. Because competitive
displacement studies were not performed, the receptor de-
scribed in the latter study cannot be classified. Badr and
coworkers reported both a high-affinity (kD 0.76 nM, Bmax 672
fmol/mg protein) and low-affinity (kD 44 nM, B max 2760 fmol/mg
protein) binding site in cultured rat mesangial cells [15]; again,
competitive displacement studies were not performed, preclud-
ing classification of the receptor types. A second study using
cultured rat mesangial cells demonstrated the presence of two
receptor classes, ETA and ETB [16]. Accurate kinetic analyses
are not available from that study. Terada and coworkers
recently identified an ETA and ETB receptor on microdissected
rat glomeruli using the polymerase chain reaction (PCR) and
Southern blot techniques [17]. Taken together, these studies
provide compelling evidence that both ETA and ETB receptors
are present within the glomerulus.
A paucity of data exists characterizing ET receptors on
different nephron segments and other intrarenal structures.
Preliminary data from my laboratory indicated that specific ET
binding sites are present on primary cultures of inner medullary
collecting duct (IMCD) cells [18]. Using a standard radioligand
displacement assay, we delineated a single class of high-affinity
receptors (kD 26 pM, Bmax 995 fmol/mg protein), conforming to
the characteristics of the ET8 type (unpublished observations).
In contrast to the IMCD cell, renal medullary interstitial cells
(RMIC) possess a single class of high-affinity receptors (kD 57
pM, Bmax 749 fmol/mg protein) of the ETA type, that is,
receptors that recognize only ET-1 and ET-2 [19]. Hence,
within the inner medulla, two juxtaposed cells with vastly
different anatomic characteristics and physiologic functions
possess different ET receptor types.
Table 1 summarizes existing knowledge about ET receptors
on various intrarenal structures. As I noted, the glomerulus
possesses both ETA and ETB receptors. Data from microdis-
sected rat nephron segments subjected to PCR and Southern
blotting indicate the presence of ETB receptors primarily in the
IMCD [17]; these results are in keeping with our own radioli-
Table 1. Endothelin receptor subtypes in renal structuresa
Structure
ETA
(ET-1 and ET-2)
ETB
(ET-1, ET-2, & ET-3)
Glomerulus + +
CCD — +
OMCD — +
IMCD — +
RMIC + -.-
VSMC + —
a Data summarized from Refs. 17—19. ET, endothelin; CCD, cortical
collecting duct; OMCD, outer medullary collecting duct; IMCD, inner
medullai-y collecting duct; RMIC, renal medullary interstitial cell;
VSMC, vascular smooth muscle cell.
gand binding data [19]. Small signals for ET receptors also
were detected on the cortical collecting duct (CCD) and outer
medullary collecting duct (OMCD). We were interested to note
that the PCRlSouthern blot analysis failed to detect ET recep-
tors on proximal tubule segments. Vascular smooth muscle
cells obtained from arcuate arteries display ETA receptors [17]
as do RMIC [19]. It is very interesting that cells with a common
mesenchymal origin (that is, mesangial cells, vascular smooth
muscle cells, and renal medullary interstitial cells) possess ETA
receptors, whereas cells of epithelial origin possess ETB recep-
tors. The significance of this observation is not known.
Biochemical mechanisms of renal ET action
Accumulating evidence suggests that ET mediates its effects
in different nephron segments, as well as in other renal struc-
tures, via a multiplicity of intracellular signal transduction
pathways. Studies from our laboratory have shown that in
cultured RMIC, ET stimulates phosphatidylinositol (P1) hydro-
lysis [19]. Indeed, inositol-trisphosphate (1P3)-mediated release
of Ca2 from intracellular stores could be detected at an agonist
concentration as low as ' M, with a K05 of approximately
l0 10 M. Endothelin also activates phospholipase A2 (PLA2) in
a time- and concentration-dependent manner, as evidenced by
(1) prostaglandin E2 (PGE2) production; (2) release of labeled
arachidonic acid into the bathing medium; and (3) immunohis-
tochemical staining of cells for PLA2 with a polyclonal antibody
[20, 21]. Phosphatidylethanolamine, rather than phosphatidyl-
inositol, is the prime substrate for PLA2 action. Furthermore,
when a very low concentration (l0 M) of phorbol-12,l3-
myristate (PMA) was used to inhibit phosphatidylinositol-spe-
cific phospholipase C (P1-PLC), agonist-evoked PGE2 accumu-
lation was not abrogated [21]. Finally, down-regulation of
protein kinase C (PKC) (confirmed independently) did not
mitigate ET-mediated eicosanoid production [21]. These obser-
vations provide compelling evidence that PLA2 is coupled
directly to the ETA receptor and is not dependent on stimula-
tion of P1 hydrolysis in this cell type.
In addition to verifying activation of P1-PLC and PLA2, we
have demonstrated that ET stimulates two enzymes that hydro-
lyze phosphatidylcholine (PC), namely, PC-specific phospho-
lipase D (PC-PLD) and PC-specific phospholipase C (PC-PLC).
PC-PLD activation [22, 23] is suggested by the observation that
endothelin promotes the accumulation of phosphatidic acid
(PA) and, in the presence of ethanol, also promotes accumula-
tion of phosphatidylethanol (PEt); the transphosphatidylation
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Fig. 2. Principal hydrolysis products of
phosphatidvlcholine (PC) and
phosphatidylinositol (P1) hydrolysis by PC-
spec jfic phospholipase D (PC-PLD) and P1-
specific phospholipase C (P1-PLC),
respectively and their interactions. PC-PLD
hydrolysis of PC yields phosphatidic acid (PA)
and choline. Phosphatidylethanol (PEt) is the
transphosphatidylation product derived in the
presence of ethanol, but is not a naturally
occurring product of PC-PLD hydrolysis and
is included purely for schematic purposes.
P1-PLC hydrolyis of P1 yields diacylglycerol
(DAG) and inositol trisphosphate (1P3) which
in turn releases Ca2 from intracellular
organelles (Ca21). DAG may be metabolized
to PA via DAG kinase. PA may be
dephosphorylated to DAG via PA-
phosphohydrolase (PAP). DAG is the prime
stimulator of protein kinase C (PKC).
reaction responsible for PEt accumulation is considered PLD
specific [241 and produces a more stable product than does the
naturally occurring PA (Fig. 2). Inhibition of diacylglycerol
(DAG) kinase, the enzyme that converts DAG to PA, fails to
blunt PA accumulation; PLD and not DAG thus is likely the
primary source of PA (Fig. 2). Indeed, inhibition of PA phos-
phohydrolase (PAP), the enzyme that dephosphorylates PA to
DAG, increased accumulation of PA at later time points (Fig.
2). This finding suggests that the prevailing "metabolic flow" is
in the direction of PA to DAG. Phospholipase D appears to be
under the dual regulation of PKC and Ca2, with PKC being the
major regulator of the enzyme and Ca2 playing a secondary,
modulatory role. Furthermore, the observation that PMA ab-
rogates P1 hydrolysis but augments PC-PLD action argues that
ET-mediated PC-PLD stimulation is not a secondary event
consequent to P1-PLC activation, but rather that the ET recep-
tor also is coupled directly to PC-PLD. That P1-PLC hydrolyzes
P1 and that PC-PLD hydrolyzes PC adds credence to this
conclusion,
The role of PC-specific phospholipase C in mediating the
actions of ET is currently under investigation [25]. Endothelin
stimulates the accumulation of phosphorylcholine in a time- and
concentration-dependent manner, with a parallel increment in
DAG derived principally from PC. In contrast to PC-PLD,
PC-PLC is modulated primarily by influx of Ca2 into the cell
via receptor-operated Ca2 channels rather than by PKC,
which appears not to play a role in the activity of this enzyme
(unpublished observations). It is likely, but not yet proven, that
ET-induced PC-PLC hydrolysis of PC is the major mechanism
whereby elevated DAG levels are sustained in this cell type.
Endothelin also activates receptor-operated Ca2 channels in
RMICs [171. The channels are dihydropyridine-insensitive, but
can be blocked with Ni2, an inorganic Ca2 channel inhibitor.
It is interesting that ET stimulates channel activity at agonist
concentrations well below those required to activate the P1
pathway. This observation argues, at least in RMICs, that
intermediates of P1 hydrolysis are not involved in ET-receptor-
mediated Ca2 channel operation [261. We don't yet know
whether Ca2 efilux from intracellular stores mediated via
mechanism(s) other than 1P3 release plays a role in agonist-
related receptor operation. Using cultured mesangial cells, on
the other hand, Jijima and coworkers in our group have identi-
fied ET-stimulated dihydropyridine-sensitive Ca2 channels
[271. In their construct, increments in intracellular ECa2]
activated Cl channels with a resultant efflux of Cl from the
cell. Consequent to the Cl efflux, there is an ensuing mem-
brane depolarization that leads to activation of voltage-depen-
dent Ca2 channels.
Little is known regarding downstream events in the ET
intracellular transduction cascade. Evidence suggests that, in
cultured mesangial cells, ET increases protein tyrosine phos-
phorylation (PTP) of five different proteins of molecular mass
ranging from 225 kD to 70 kD t28]. The PTP appeared to
proceed via at least two pathways, namely PKC-dependent and
PKC-independent. Given that binding of the agonist to the ET
receptor is not known to induce tyrosine autophosphorylation,
one can reasonably conclude that novel proteins of undeter-
mined function are being phosphorylated. Whether P1'P of
these proteins is a consequence of ET activation of one of the
signal transduction mechanisms remains to be evaluated. It is
equally possible that PTP of one or another protein might be a
common denominator in the action of ET.
In a preliminary report, Owada and coworkers noted that
ET-3 stimulated cGMP production via nitric oxide in isolated
rat glomeruli but not in microdissected inner medullary collect-
ing ducts [29]. The L-arginine analogue, NG monomethyl-L-
arginine (L-NMMA), completely abolished ET-3-induced
cGMP; this finding indicates that ET mediates its effect via
stimulation of nitric oxide synthetase (NOS). Tereda and col-
leagues subsequently reported that constitutive NOS mRNA is
most abundant in the IMCD; smaller amounts are detected in
glomeruli, with PCR/Southern blot analysis [301. Glomeruli, on
Choline
A Ca2
Phosphatidic
Acid (PA)
DAG Kinase
PA phosphohydrolase
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Table 2. Mechanisms of endothelin's action in renal structuresa
Mechanism Glomerulus IMCD RMIC
P1PLCb + ÷ ÷
PLA2 + + +
PC-PLC + ND +
PC-PLD + ND +
Ca2 channel + + +
cGMP + - ND
PTP + ND ND
a Data summarized from Refs. 18—31.b P1-PLC, phosphatidylinositol-specific phospholipase C; PLA2,
phospholipase A,; PC-PLC, phosphatidyicholine-specific phospho-
lipase C; PC-PLD, phosphatidyicholine-specific phospholipase D;
cGMP, cyclic guanosine monophosphate; PTP, protein tyrosine phos-
phorylation; ND, not done.
the other hand, express large amounts of soluble guanylate
cyclase mRNA, and relatively small amounts of this material
are detected in the IMCD [301. The precise role of ET-evoked
NOS stimulation in deactivating ET effect is currently the
subject of intense investigation.
Table 2 summarizes the mechanisms of endothelin's action in
the three renal structures or cell types that have been most
extensively studied. Studies in cultured IMCDs and RMICs
have been performed primarily in our laboratory, whereas those
in glomerular cells have been reported by a number of workers
[311. As noted, the ET receptor appears to be linked to many
intracellular signal transduction pathways. Furthermore, a
number of the effector units (P1-PLC, PLA,, and PC-PLD)
appear to be coupled directly to the ET receptor. Why the ET
receptor should be coupled in this manner to multiple intracel-
lular signal transduction cascades is not known. The mecha-
nism(s) whereby these different pathways interact with one
another is the subject of ongoing studies.
Sites of renal ET production
Endothelin is produced in the kidney both by endothelial and
non-endothelial cells. Endothelin-like immunoreactivity was
found by the immunoperoxidase technique to be widely distrib-
uted in normal rat kidney exposed to a polyclonal antibody
raised in rabbit [32]. Immunostaining density was greatest in the
renal papilla where staining was localized to the vasa rectae and
epithelial cells of the IMCD (Fig. 3). Cortical immunostaining
was localized to the endothelial surface of arcuate arteries,
veins, arterioles, and peritubular capillaries. Glomerular immu-
nostaining followed a capillary loop distribution, and it ap-
peared to be primarily localized to endothelial cells, with
smaller amounts of staining observed in mesangial cells (Fig. 4).
The brush-border membrane of the most proximal portion of
the proximal tubule demonstrated focal immunostaining. On the
basis of these observations, we have obtained a more precise
cellular localization of ET production.
In the glomerulus, evidence is compelling that ET is synthe-
sized by mesangial, endothelial, and epithelial cells (Table 3).
Cultured human mesangial cells produce ET- 1 as measured by
radioimmunoassay (RIA), and this effect is augmented by AVP
[33]. Bovine glomerular capillary endothelial cells in culture
release ET-1 in a time-dependent fashion, and the effect is
increased by challenging cells with bradykinin [34]. PreproET-!
mRNA levels rose in a biphasic manner in response to brady-
kinin administration; the early-phase increment did not depend
on new protein synthesis, whereas the late rise appeared to be.
More recently, cultured bovine glomerular epithelial cells were
shown to synthesize ET-l and ET-3 [35]. Similar results were
reported in cultured rat glomerular epithelial cells [36]. Why
three different glomerular cells possess the ability to produce
ET is not known.
Studies from several laboratories indicate that only certain
nephron segments synthesize ET. These studies are summa-
rized in Table 4. Endothelin production in the IMCD has been
demonstrated via a variety of tissue preparations and assays.
Kohan detected both ET-l and ET-3 (ET-1 >> ET-3) in
cultured rabbit IMCD cells by RIA [37]. Uchida and coworkers
detected ET-l mRNA in microdissected rat IMCD tubules
subjected to the reverse transcriptase polymerase chain reac-
tion (RT-PCR) [38]. Using a similar method, Ujiie and col-
leagues reported identical findings [39]. Schnermann et al
detected an abundance of ET-3 mRNA by immunofluorescence
and preproET-3 mRNA by RT-PCR; no mention was made of
ET- 1 production in this study [40]. We have detected ET- 1 and
ET-3 using immunohistochemical techniques in cultured rat
IMCD cells [41]. It is interesting that brief exposure of cells to
hyperosmolar solutions (NaC1, mannitol, and urea) enhanced
ET-l immunostaining strikingly, whereas exposure of cells to a
hypoosmolar solution essentially eliminated the baseline signal.
Whether other nephron segments synthesize ET is much less
clear. Furthermore, species differences might exist. Rabbit and
mouse proximal tubule appear to synthesize ET-l [37, 42]; rat
proximal tubule does not [38, 39]. Rabbit medullary thick
ascending limb (MTAL) synthesizes more ET-1 than ET-3 [37],
but neither peptide Was detected in rat MTAL [38, 39]. Rabbit
cortical collecting duct (CCD) produces ET [37] but rat CCD
might not; ET-l was detected in this segment in one study in the
rat [38] but not in a second study using an identical approach
[39]. Conflicting data also have been reported for the rat
OMCD. Taking all the data into account, however, the IMCD is
generally agreed to be a major site of ET production. Whether
additional nephron segments synthesize the peptide is not
settled.
Physiology
Whole-organ studies in intact rats have demonstrated that
infusion of ET into the renal artery at a rate of 5—40 pmol/hr
decreases renal plasma flow (RPF), glomerular filtration rate
(GFR), and urine volume [43]. Fractional excretion of Na
(FENa) did not change appreciably under these conditions, nor
did centrally measured mean arterial pressure (MAP). The
decrease in renal plasma flow in the presence of a constant
MAP is consistent with a direct action of the peptide on the
kidney. The most likely explanation for these findings is ET's
potent vasoconstrictor effect. The observation that the Ca2
channel blocker nicardipine diminishes ET-induced reduction
in urine volume, GFR, and RPF is in keeping with the view that
ET mediates its profound vasoconstrictor effects via receptor-
operated Ca2 channels. Essentially identical results have been
reported in the dog [441. Given these observations in the whole
animal, and the finding that radiocontrast medium stimulates
release of ET from cultured cells [59, 61], it is not difficult to
envision how infusion of radiocontrast medium might adversely
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Fig. 3. Endothelin-like immunostaining in renal medulla and papilla, Endothelin-like immunostaining is present in peritubular capillaries of inner
medulla with increasing intensity of immunostaining in deeper regions. Staining is most intense along endothelial surfaces of vasa recta.
Cytoplasmic immunostaining is also present in afew epithelial cells lining collecting ducts. Magnification x 125. (Reproduced with permission from
Ref. 32.)
affect renal function, especially in individuals with already
compromised kidneys.
Micropuncture studies have further elucidated the mecha-
nism(s) by which ET decreases GFR. Endothelin increases
afferent and efferent arteriolar resistance (afferent somewhat
more than efferent), thereby reducing nephron plasma flow rate;
ET also reduces the glomerular ultrafiltration coefficient (Kr)
and hence diminishes single-nephron GFR (SNGFR) [451.
Other reports generally agree with these observations. In one
study, afferent and efferent arteriolar resistances were in-
creased and K was decreased, but SNGFR was not signifi-
cantly diminished because the decrement in K was offset by a
concomitant increase in glomerular capillary hydrostatic pres-
sure [46]. In another study [50], afferent arteriolar resistance
Was increased to a greater extent than was efferent arteriolar
resistance and Kr Was unchanged, but SNGFR was diminished
consequent to the profound reduction in RIP [47]. The some-
what discrepant findings in these studies likely are related to
differences in the specific experimental protocols used.
Edwards and coworkers have examined the sensitivity to ET
of microdissected afferent and efferent glomerular arterioles
from the rabbit [48]. Afferent as well as efferent vessels re-
sponded to ET-1 and ET-2; similar EC50 values were found for
both peptides in both structures. On the other hand, ET-3 was
considerably less potent. It is interesting that inhibition of the
ET-mediated vasoconstrictor effect by dihydropyridines oc-
curred exclusively in afferent arterioles. Whether efferent ves-
sels possess dihydropyridine-insensitive or phenylalkylamine-
insensitive Ca2 channels was not determined. In a preliminary
report, indomethacin mitigated the prolonged vasoconstrictive
effects of ET on microperfused afferent and efferent vessels but
had little effect on maximal contraction [491. These authors
surmised that the sustained vasoconstrictive actions of ET are
mediated by cyclooxygenase-dependent intermediates synthe-
sized as a consequence of ET binding to its receptor. Taken
together, the evidence is convincing that arteriolar vasocon-
striction plays a predominant role in the changes in glomerular
function following challenge with ET.
Perhaps the most firmly established tubular action of ET is its
ability to inhibit the hydroosmotic effect of AVP, particularly in
the IMCD. Oishi and coworkers demonstrated in the isolated
perfused IMCD that ET at 10— '° to lO M reversibly inhibited
AVP-stimulated water permeability but did not augment AVP-
stimulated urea permeability [50]. Because ET failed to blunt
the augmented water permeability induced by dibutyryl cAMP,
the authors concluded that ET exerts its effect at a site proximal
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Fig. 4. Endothelin-like immunostaining in rat renal glomerulus. Kidney sections were immunostained using specific endothelin 1 antiserum
(1:1000). Photomicrograph demonstrates granular and linear immunostaining along glomerular capillary loops and in mesangial regions.
Endothelin-like immunostaining is also seen in peritubular capillaries. Magnification x 375. (Reproduced with permission from Ref. 32.)
Table 3. Glonserular sites of endothelin production
ET
Reference Cell type isoform' Assay
33 Human MC
(culture)
1 kIA
34 Glom endo cell
(culture)
1 RIA
Northern blot
35 Glom epi cell
(culture)
1, 3 RIA
Northern blot
36 Glom epi cell
(culture)
1 RIA
a ET, endothelin; MC, mesangial cell; Glom endo cell, glomerular
endothelial cell; Glom epi cell, glomerular epithelial cell; RIA, radio-
immunoassay.
to cAMP generation. In a separate study, these workers sug-
gested that ET mitigates the hydroosmotic effect of AVP via
PKC inhibition of cAMP [511. Neither Ca2 channel blockers
nor inhibition of PGE2 synthesis was effective in blocking ET's
effect. Unfortunately, no independent evidence was provided to
confirm that dihydropyridine-sensitive channels exist in this
preparation, and the authors' conclusions were somewhat
weakened. Nadler and coworkers reported that ET blunted the
hydroosmotic effect in IMCD via a pertussis-toxin-sensitive
pathway that is only partially PKC dependent [52]. The obser-
vation that changes in osmolarity modulate ET production in
this nephron segment [53] supports the notion that ET might be
an autocrine regulator of water flux in distal nephron segments.
An autocrine and paracrine role for ET within the inner medulla
is schematicaly depicted in Figure 5. According to this schema,
ET synthesis induced by increases in osmolarity, or other
yet-to-be identified trigger mechanisms, results in the paracrine
(RMIC) or autocrine (IMCD) action of the peptide. Endothe-
lin' s inhibition of the hydroosmotic effect of AVP could serve to
"fine tune" water absorption at the major site of AVP action
(IMCD) and hence might be the final determinant of the solute
concentration of urine, particularly in the setting of increased
solute diuresis. The precise mechanism by which ET blunts the
hydroosmotic effect of AVP remains to be determined. Endo-
thelin also appears to mitigate the hydroosmotic effect of AVP
in the CCD and OMCD via mechanisms similar to those in the
IMCD.
Preliminary studies in rabbit CCDs indicate that ET might
inhibit luminal amiloride-sensitive Na channels [54J; the effect
appeared to require Ca2. If this observation is confirmed, it
might explain in part the natriuretic effect of ET reported by
some workers [461.
The proximal tubule was recently identified as a possible site
of ET action; in rat proximal straight tubule, presumably S3, ET
(lO) diminished fluid absorption and concomitantly blunted
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Table 4. Tubular sites of endothelin production
FT
Ref PT MTAL CCD OMCD IMCD isoform Assay
37 -I- + i- ND ++ 1,3 MA
38 — — + + + 1 PCR
39 — — — — -I--I- 1 PCR
40 ND ND ND ND + 3 Immuno
PCR
41 ND ND ND ND ++ 1,3 Immuno
42 + ND ND ND ND I Immuno
(TNF)
a PT, proximal tubule; MTAL, medullary thick ascending limb; CCD, cortical collecting duct; OMCD, outer medullary collecting duct; IMCD,
inner medullary collecting duct; ET, endothelin; RIA, radioimmunoassay; PCR, polymerase chain reaction; Immuno, immunohistochemistry;
TNF, tumor necrosis factor; ND, not done.
Fig. 5. Depiction of an autocrine and/or
paracrine role for endothelin (ET) in blunting
the hydroosmotic effect of arginine
vasopressin (A VP) acting via its V2 receptor.
Ca, increments in intracellular calcium; AA,
arachidonic acid or its metabolites; PKC,
protein kinase C; PA, phosphatidic acid; PC,
other product of phosphatidylcholine
hydrolysis.
bicarbonate absorption [55]. Because FT also inhibited Nat-
K-ATPase activity in the same preparation, the authors con-
cluded that ET mediated its effect on fluid and bicarbonate
absorption via inhibition of Na-K-ATPase. Although ET
inhibited Na pump activity, the reduction was modest,
amounting to only 20% of ouabain-sensitive enzyme activity. In
contrast to these findings, ET had no effect on rabbit proximal
tubule Na-K-ATPase activity [56]. On the other hand, ex-
periments performed in basolateral membrane vesicles pre-
pared from rabbit renal cortex demonstrated that ET acceler-
ated Nat-HC03 cotransport (increase in Vmax but no change
in Km) [57]. These findings suggest that ET modulates bicar-
bonate reabsorption independently of actions on the Na
pump. The latter study also reported that FT directly stimulates
the Na/H antiporter (increase in V,nax but no change in Km)
in brush-border membrane vesicles; this finding is in keeping
with FT stimulation of bicarbonate reabsorption. In rat brush-
border membrane vesicles, FT stimulated the Na7H an-
tiporter and Na-phosphate cotransport in a biphasic manner
[58]. At physiologic concentrations of ET (l0——l0—1' M), both
transport pathways were stimulated; at higher concentrations of
agonist (l0— M), both mechanisms were blunted. Pre-incuba-
tion of the preparation with staurosporine, an inhibitor of
protein kinase C, abolished all effects of ET on both pathways.
In summary, data conflict regarding the precise role of FT in
proximal tubule function. Interpretation of the evidence is
further complicated by the fact that no receptors for FT have
yet been identified in the proximal nephron [17]. Whether the
proximal tubule possesses a unique FT receptor is currently not
known.
Possible role of ET in contrast-induced nephropathy
In the patient presented here, the increase in serum creatinine
accompanied by a decrease in urine output occurring within 24
hours of exposure to radiographic contrast medium and in the
absence of alternative causes of acute renal impairment is
strong circumstantial evidence for contrast-associated nephrop-
athy. Significant risk factors for this entity in this patient
include pre-existing renal disease (on the basis of diabetes
mellitus), hypertension, advanced age, and congestive heart
failure.
Recent studies in normal rats have incriminated endothelin in
the pathophysiology of radiocontrast-induced nephropathy
[59]. Plasma FT levels doubled within 10 to 15 minutes follow-
ing intravenous injection of the ionic compound, remained
elevated through 30 minutes, and returned toward baseline by
60 minutes, the latest timepoint measured [591. Renal blood
PGE2...._ ,
Other
eicosanoids
Medullary Inner medullary
interstitial cells collecting duct cells
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flow increased initially (that is, at 2 minutes) then fell approxi-
mately 15% by 10 minutes; renal blood flow returned towards
baseline levels by 30 minutes. Similar effects were elicited using
"high-osmolar," "low-osmolar," and non-ionic agents contain-
ing similar amounts of iodine. Infusion of hypertonic solutions
of sodium chloride, mannitol, or glucose were without effect. In
a separate study, increased plasma and urinary endothelin
levels were detected in an animal model at high risk for
contrast-induced nephropathy, namely animals with experi-
mental congestive heart failure [60]. Exposure of cultured
bovine endothelial cells to radiocontrast agents also induced
ET-1 release [59], and ET-1 mRNA was detected within 15
minutes [61]. However, a cause-and-effect relationship between
radiocontrast-evoked ET production and elevated serum ET
levels, on the one hand, and the pattern of renal insufficiency
seen in this entity, on the other, remains to be established.
Future directions
Although much information regarding the renal actions of ET
has become available over a relatively short period, we are still
only at the threshold of understanding the complex role of this
newly discovered peptide in renal physiology and pathophysi-
ology. The functional relevance of having ETA receptors on
mesangial, vascular smooth muscle, and medullary interstitial
cells and of having ETB receptors on the epithelial cells of the
collecting duct, and in particular the inner medullary collecting
duct, needs to be elucidated. An integrated understanding of the
interactions among the various intracellular transduction path-
ways activated by ET might shed light on whether specific
transduction pathways are linked to specific physiologic events.
Furthermore, mechanisms whereby these pathways might am-
plify or abrogate one another's effects require additional inves-
tigation. The role of locally synthesized ET and the factors that
mediate local release by different nephron structures are of
particular interest. The observations that IMCD cells both
synthesize and respond to ET, and that ET synthesis in this
nephron segment is modulated by changes in osmolarity is
particularly intriguing. The signal whereby changes in osmolar-
ity are "sensed" by the cell is currently not known. Finally, the
role of ET in different pathophysiologic states requires further
investigation. The relevance of plasma and/or urinary levels of
ET is currently not known and might be of relatively little
importance if the paracrine and autocrine actions of ET pre-
dominate. In the context of contrast-induced acute renal insuf-
ficiency, the discrepancy between the relatively short period of
hemodynamic derangements and the prolonged effect of con-
trast media on renal function awaits resolution.
Questions and answers
DR. FREDERICK MILLER (Chair, Department of Pathology,
State University of New York at Stony Brook, Stony Brook,
New York): I'm curious about the sites of production of
endothelin. Recent in-vitro studies from Marsden's group indi-
cate that endothelin is produced by epithelial and endothelial
cells, in addition to mesangial cells [62]. Do we know which of
these sites of production is physiologically important in the
intact individual?
DR. NORD: The sites of endothelin production within the
intact glomerulus have not been precisely defined to date. The
studies you allude to involve cells in culture. The answer to this
question awaits application of the technique of in-situ reverse
transcription, followed by the polymerase chain reaction and
then in-situ hybridization. Until such experiments are done, it is
not unreasonable to propose that mesangial cell production of
the peptide might be most relevant physiologically.
DR. LEONARD MEISELAS (Department of Medicine, State
University of New York at Stony Brook): Do other substances
besides radiocontrast dyes, for example, nonsteroidal antiin-
flammatory agents, influence endothelin secretion? And might
increased endothelin production in the kidney be a common
pathway by which multiple agents stimulate PGE2 synthesis?
DR. NORD: Nonsteroidal antiinflammatory agents have not
been shown to influence renal endothelin production. Throm-
bin, epinephrine, and TGF, are well-described factors that
stimulate endothelin production, to name but a few. Increased
endothelin production in the kidney is not likely to be a
common pathway by which agonists stimulate PGE2 production
because cells that do not synthesize endothelin, for example,
renal medullary interstitial cells, synthesize PGE2 in response
to an array of agonists.
DR. JORDAN J. COHEN (Dean, School of Medicine, State
University of New York at Stony Brook): In the studies dem-
onstrating endothelin release from cultured endothelial cells
challenged with radiocontrast dyes, was the concentration of
radiocontrast material used comparable to the circulating levels
achieved in patients?
DR. NORD: Cultured cells were exposed to 20 sl of radiocon-
trast dye per ml of culture medium; rats were injected with a
dose of 6 ml/kg body weight [56]. These values cannot be
readily compared, although the authors of the manuscript state
that the cells were exposed to amounts of radiocontrast medium
comparable to those sometimes employed for extensive angio-
graphic examination of patients [59].
DR. COHEN: Given the speculation that nonionic contrast
material is less nephrotoxic than the ionic forms, do we know
whether the non-ionic forms cause endothelin release from
cultured endothelial cells?
DR. N0RD: Ionic and non-ionic compounds elicit the produc-
tion of similar amounts of endothelin in cultured cells.
DR. GEORGE KALOYANIDES (Division of Nephrology, State
University of New York at Stony Brook): You indicated that
hyperosmolarity of some degree is sufficient to stimulate release
of endothelin from epithelial cells in the inner medullary col-
lecting duct. Is it known how that signal is transduced?
DR. NORD: No, the mechanism has not yet been elucidated.
DR. KALOYANIDES: I'm intrigued by the data suggesting that
endothelin antagonizes the action of arginine vasopressin.
Given its vasoconstrictor properties, it is conceivable that
endothelin might diminish inner medullary blood flow by acting
at the level of the vasa recta and thereby augment the effects of
arginine vasopressin on water flow. Are there data documenting
endothelin's influence on vasa recta blood flow in the kidney?
DR. NORD: The question you raise is an important one, and
our initial hypothesis as to how endothelin might modulate
water reabsorption at the level of the collecting duct proposed
the mechanism you suggest. Indeed, we detected endothelin in
the endothelial cells of the vasa recta of rat kidney by immu-
nostaining [32]. Since measurements of vasa recta contractility
are technically extremely difficult, this issue is not yet resolved.
DR. MICHAEL GOLLGORSKY (Department of Medicine and of
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Physiology and Biophysics, State University of New York at
Stony Brook): It's interesting to note the differences between
endothelin's effect on the vasa recta, on the one hand, and its
effect on the inner medullary collecting duct, on the other. At
the level of vasa recta, ET would seem to enhance water
conservation; at the level of the inner medullary collecting duct
epithelium, ET impedes water conservation because it blunts
the effect of AVP. It's also interesting to note that the inner
medullary collecting duct produces large amounts of nitric
oxide, which counterbalance the effect of endothelin [30].
I also have a question about the patient presented here. This
man apparently had a non-Q-wave myocardial infarction. Re-
cent observations indicate that patients with myocardial infarc-
tion or unstable angina have increased circulating levels of
endothelin [63]. Interestingly, a good correlation exists between
circulating levels of endothelin and the size of the myocardial
infarction as judged by CPK levels. Therefore, some elevation
in circulating endothelin might have been an additional factor
leading to the radiocontrast-induced nephrotoxicity.
May I make one final point: Dr. Gordienko in my laboratory
recently demonstrated with the whole-cell patch clamp tech-
nique that in microdissected arcuate arteries, endothelin causes
an increase in chloride channel activity as well as an increase in
L-type calcium channel activity [64].
DR. NORD: Let me make two points in response to your
comments. First, increased circulating levels of endothelin have
been reported in a number of clinical entities, myocardial
infarction being but one example. In this instance increased
endothelin production may be the consequence of the action of
local factors, such as thrombin release, rather than the major
factor responsible for vasoconstriction. Stated differently, cur-
rent data are inconclusive as to whether circulating endothelin
levels are the cause or the effect of a given pathologic entity.
Second, with regard to the mechanism of endothelin-related
activation of Ca2 channels, a number of potential mechanisms
have been identified whereby channel activity might be in-
creased. In renal medullary interstitial cells, for example, Ca2Th
channel activity can be completely dissociated from activation
of the IP pathway [19], an essential element of the calcium-
mediated chloride channel hypothesis.
DR. COHEN: You noted that endothelin is present in large
quantities in the posterior pituitary of hydrated animals but that
it disappears following water deprivation. First, do we know
that this disappearance is associated with actual secretion of
endothelin into the circulation?
DR. N0RD: Circulating levels of endothelin were not reported
in that manuscript.
DR. COHEN: Second, does circulating endothelin increase
measurably in response to water deprivation?
DR. NORD: This has not been tested.
DR. COHEN: Finally, do we know what effect infused endo-
thelin has on urinary concentration?
DR. Noiw: Because endothelin acts at multiple sites in the
kidney, interpretation of infusion data has proven difficult.
DR. MICHAEL GEHEB (Department of Medicine, State Uni-
versity of New York at Stony Brook): I have two questions.
Hyperosmolar loading, whether in the form of contrast material
or mannitol, is known to cause an increase in renal blood flow,
initially followed by a sustained decrease that can be blunted by
volume expansion. Could augmented endothelin release be the
mechanism responsible for the sustained decrease? My second
question is a clinical one. Do you think pretreatment with a
renal vasodilator, an endothelin antibody, or an anti-receptor
molecule might prevent radiocontrast-induced renal failure?
DR. NORD: In answer to your first question, the role of
endothelin in modulating renal blood flow under conditions of
osmolar loading has not been specifically evaluated. With
regard to your second question, it is common experience that
transient renal insufficiency may ensue despite rigorous volume
expansion accompanied by brisk diuresis. Hence pretreatment
with vasodilators prior to radiocontrast infusion in all likelihood
would not be efficacious. The potential role of an endothelin
antibody or an anti-receptor molecule in this setting awaits
resolution.
DR. MARTIN LIEBOWITz (Department of Medicine, State
University of New York at Stony Brook): Would you speculate
on the evolutionary significance of this compound? The fact
that endothelin is produced in circumstances in which antidi-
uretic hormone is also secreted, and yet antagonizes to some
degree the effect of antidiuretic hormone, raises questions
about the role of endothelin in water homeostasis.
DR. NORD: The fact that endothelin is secreted by the
posterior pituitary under identical circumstances that evoke
vasopressin release is intriguing. However, this might simply be
a vestigial evolutionary remnant; the autocrine role of endothe-
lin in the collecting duct appears to be of greater physiologic
relevance than its endocrine role, at least in mammals. I am
unaware whether endothelin secretion in non-mammals has
been scrutinized.
DR. MATHI ILAMATHI (Chief of Nephrology, St. John's
Episcopal Hospital, Smithtown, New York): Do you think that
pretreating patients with inhibitors of angiotensin converting
enzyme might have an effect on radiocontrast-iaduced nephrop-
athy similar to that reported with calcium channel blockers?
DR. NORD: Pretreatment of patients with inhibitors of angio-
tensin converting enzyme prior to exposure to dye does not
appear to mitigate the nephrotoxic effect.
DR. COHEN: As you noted, patients with diabetes mellitus
appear to be especially susceptible to radiocontrast-induced
nephropathy. Is there any reason to think that endothelin's role
can explain this susceptibility?
DR. NORD: No.
DR. BARRY COLLER (Chief of Hematology, State University
of New York at Stony Brook): Has the three-dimensional
structure of endothelin been elucidated with NMR? If so, has
anyone attempted to make congeners that might act as inhibi-
tors?
DR. NORD: The three-dimensional structure of endothelin has
been studied by NMR [65, 66]. Perhaps the most widely tested
inhibitor of endothelin's actions is phosphoramidon [67]. The
inhibitory effect of this compound is mediated via inhibition of
endothelin converting enzyme, which is responsible for the
intracellular conversion of the endothelin precursor, big endo-
thelin, to endothelin.
DR. COHEN: You noted that the endothelin receptor appears
to be linked to more than one intracellular cascade. Knowing
that there are at least two receptor types, are we certain that a
given receptor type is linked to more than one intracellular
mechanism?
DR. NORD: It is clear both from the microdissected tubule
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data and standard radioligand binding kinetics that in nephron
segments or intrarenal structures other than the glomerulus, a
single endothelin receptor is present. Thus multiple intracellular
signal transduction pathways appear to be linked to a single
receptor. How these signal transduction pathways "speak" to
one another and at what level differential regulation occurs is
currently not known. Parenthetically, the acetyicholine recep-
tor provides a well-established precedent for such a model.
DR. COHEN: Is the endothelin released from the posterior
pituitary endothelin-3, which would seem to be most in keeping
with a targeted action in the inner medulla?
DR. NORD: Only endothelin-1 was examined. Recall, how-
ever, that the inner medullary collecting duct possesses the ETB
receptor so that both endothelin-l and endothelin-3 would be
recognized.
DR. COHEN: What is the proximate stimulus to endothelin
release or production by glomerular cells?
DR. NORD: A number of agonists are responsible for glomer-
ular stimulation of endothelin release: bradykinin, thrombin,
and TGF,3 are but a few. All these compounds are well-
described stimulators of endothelin release.
DR. COHEN: Does that suggest that endothelin might play a
role in other forms of acute renal failure in addition to radio-
contrast-induced ATN?
DR. NORD: There is no convincing evidence that endothelin is
an important pathophysiologic factor in acute renal failure.
DR. GEHEB: To postulate a role for endothelin in clinical
acute renal failure, I would think it important to know how
various vascular changes such as hypertension, on the one
hand, and hypotension, on the other hand, affect endothelin
production.
DR. NORD: The effect of endothelin is to cause vasoconstric-
tion. The renal hemodynamic effects have been demonstrated in
the absence of any changes in the systemic blood pressure.
Whether changes in blood pressure modulate endothelin pro-
duction is difficult to demonstrate.
DR. COHEN: Do nonvascular receptors for endothelin exist in
nonrenal tissue?
DR. NORD: Yes. Endothelin receptors have been described
on a number of nonvascular cells in nonrenal tissue. Cultured
human breast epithelial cells, osteoblasts, myocytes and, inter-
estingly, cells of the parathyroid glands all express endothelin
receptors, to mention only a few. In most instances, the precise
physiologic role of endothelin in the biology of these cell types
remains to be elucidated.
DR. NORMAN SABI0 (Fellow, Division of Infectious Disease,
State University of New York at Stony Brook): How would you
compare the potency of angiotensin and endothelin as vasocon-
strictors?
DR. NORD: Endothelin appears to be a far more potent
vasoconstrictor than angiotensin. Its action, at least on vascular
smooth muscle cells, is also more prolonged.
DR. KALOYANIDES: Given the vasoconstrictor effects of this
peptide, does any evidence suggest a role for endothelin in
some of the more common forms of hypertension?
DR. NORD: Plasma endothelin levels have been found to be
elevated in hypertensive individuals [681. Unfortunately, con-
siderable overlap in endothelin levels between hypertensive and
normotensive subjects has been observed. Also, no difference
between borderline hypertension and normotension could be
found. In summary, it is doubtful whether elevated circulating
endothelin levels are important in the pathophysiology or the
cause of hypertension.
DR. MtLLER: If I'm not mistaken, glial cells also produce
endothelin. This observation prompts me to ask whether some
commonality exists between the CNS-acting peptides. Is there
a reno-neural axis, if you will? I have a second question. Has
anyone examined the role of endothelin in living organisms by
giving blocking antibodies directed against this polypeptide and
observing the physiologic response?
DR. N0RD: You are correct; glial cells do produce endothelin.
Whether a commonality with renal epithelial cells exists is
speculative. In answer to your second question, I am unaware
that blocking antibodies directed against this peptide have been
injected into the living organism to evaluate its physiologic
response.
DR. COHEN: As you noted, without evidence for a receptor to
endothelin being present in the proximal tubule, it is difficult to
be confident that the substance has any effect at this level. What
is your view about this issue? Do you think endothelin might
have a significant physiologic or clinical effect on proximal
tubule transport?
DR. NORD: Within the kidney the major sites of action of
endothelin are the glomerular tuft and inner medullary collect-
ing duct. At least two different laboratories have observed an
effect of endothelin on proximal tubule transport. At least two
possible explanations can be proposed. Either a technical or
experimental error exists with the receptor or transport assays.
Alternatively, the proximal tubule cell might possess a unique,
currently undiscovered receptor.
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